Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Goals
Fat LossMuscle BuildingInjury HealingAnti-AgingCognitive EnhancementSleep OptimizationImmune SupportGut HealingSkin RejuvenationSexual Health
Peptides
Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PNC-27
Cancer Research
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 32
Back to Home

Peptide Comparison

Immunoxel (Dzherelo)vsThymosin Beta-4

Ukrainian botanical immunomodulator that supercharges tuberculosis treatment and restores immune function in HIV patients

The body's natural healing peptide that accelerates tissue repair and reduces inflammation

ImmuneHealing & Recovery

At a Glance

Quick
comparison

Dose Range

Immunoxel (Dzherelo)

25–50 drops

Thymosin Beta-4

2–5 mg

Frequency

Immunoxel (Dzherelo)

Multiple times daily

Thymosin Beta-4

Twice weekly

Administration

Immunoxel (Dzherelo)

Oral (liquid drops)

Thymosin Beta-4

Subcutaneous injection

Cycle Length

Immunoxel (Dzherelo)

8-12 weeks

Thymosin Beta-4

8-12 weeks

Onset Speed

Immunoxel (Dzherelo)

Moderate (1-2 weeks)

Thymosin Beta-4

Moderate (1-2 weeks)

Evidence Level

Immunoxel (Dzherelo)

Moderate human trials (Phase 1-2)

Thymosin Beta-4

Moderate human trials (Phase 1-2)

Efficacy

Benefit
ratings

Immunoxel (Dzherelo)
Thymosin Beta-4

TB Treatment Enhancement

Immunoxel (Dzherelo)92%
Thymosin Beta-40%

Immune Restoration

Immunoxel (Dzherelo)88%
Thymosin Beta-40%

Infection Prevention

Immunoxel (Dzherelo)80%
Thymosin Beta-40%

Wound Healing

Immunoxel (Dzherelo)0%
Thymosin Beta-495%

Inflammation Reduction

Immunoxel (Dzherelo)0%
Thymosin Beta-488%

Tissue Regeneration

Immunoxel (Dzherelo)0%
Thymosin Beta-492%

Technical Data

Compound
specifications

Immunoxel (Dzherelo)

Molecular Formula

N/A — multi-component herbal phytoconcentrate

Molecular Weight

N/A — complex botanical mixture of multiple plant compounds

Half-Life

Not precisely characterized; immunomodulatory effects develop over days to weeks of consistent dosing

Bioavailability

Good oral and sublingual bioavailability; sublingual lozenges shown equivalent to twice-daily oral liquid

CAS Number

Proprietary combination

Thymosin Beta-4

Molecular Formula

C212H350N56O78S

Molecular Weight

4963

Half-Life

Dose-dependent (increases with higher doses)

Bioavailability

100% (subcutaneous and intravenous)

CAS Number

77591-33-4

Protocols

Dosing
tiers

Immunoxel (Dzherelo)

starting

25 drops twice daily (oral liquid)

Twice daily

First 1-2 weeks

Lower dose to assess tolerance; taken with water or directly under the tongue

standard

50 drops twice daily (oral liquid) OR 1 sublingual lozenge once daily

Twice daily (liquid) or once daily (sublingual)

2-4 months

Standard clinical protocol used in Ukrainian TB treatment programs; sublingual shown equivalent to oral liquid

advanced

50 drops twice daily combined with Anemin

Twice daily

4-6 months

Enhanced protocol combining Immunoxel with Anemin for maximum cytokine modulation in severe cases

Thymosin Beta-4

Applications

Best
suited for

Immunoxel (Dzherelo)

Tuberculosis Adjunct Treatment

Immunoxel's strongest evidence is as an add-on to standard TB drugs. A meta-analysis of 6 clinical trials found patients receiving Immunoxel were 3.19 times more likely to become sputum-negative compared to TB drugs alone. In one study, 84.1% of patients converted within 1 month versus only 19% on placebo.

HIV/TB Coinfection Immune Support

For patients battling both HIV and TB simultaneously, Immunoxel offers remarkable immune benefits. Clinical trials showed CD4+ T-cell counts increased by 71.2% in just 2 months, viral load decreased significantly, and opportunistic infections dropped from 12 episodes to just 3 compared to standard therapy alone.

Drug-Resistant Tuberculosis Support

Immunoxel has been studied in multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) patients where standard treatments often struggle. Its immune-boosting effects help the body fight TB even when the bacteria resist front-line drugs.

Thymosin Beta-4

Post-Surgery Recovery

Accelerates healing of surgical wounds and reduces post-operative inflammation and scarring

Chronic Wound Management

Helps pressure ulcers, venous stasis ulcers, and other slow-healing wounds progress faster

Tissue Regeneration

Supports repair of damaged tissues from injury, burns, or degenerative conditions

Safety Profile

Side
effects

Immunoxel (Dzherelo)

Common

  • Well-tolerated in most patients
  • Mild gastrointestinal discomfort

Uncommon

  • Temporary taste changes
  • Mild allergic skin reactions
  • Mild headache

Serious

  • Potential herb-drug interactions

Thymosin Beta-4

Common

  • Injection site redness
  • Injection site swelling

Uncommon

  • Temporary mild headache
  • Mild bruising at injection site
  • Transient fatigue

Serious

  • Allergic reaction

Research Status

Safety
& evidence

Immunoxel (Dzherelo)

Evidence Level

Moderate human trials (Phase 1-2)

FDA Status

Research compound

Safety Overview

Immunoxel has demonstrated a favorable safety profile across multiple clinical trials involving hundreds of patients with TB and TB/HIV coinfection. No serious adverse events have been reported in published studies. It is approved by Ukraine's Ministry of Health and has been used clinically since the late 1980s. Side effects are generally mild and gastrointestinal in nature.

Contraindications

  • xKnown hypersensitivity to any of the plant ingredients in the formulation
  • xPregnancy and breastfeeding (insufficient safety data)
  • xSevere liver disease (contains alcohol-based extract)
  • xUse as sole therapy for TB or HIV (must be combined with standard treatment)

Thymosin Beta-4

Evidence Level

Moderate human trials (Phase 1-2)

FDA Status

Research compound

Safety Overview

Thymosin Beta-4 is a naturally occurring peptide found in all cells and body fluids in the human body. Clinical trials have demonstrated excellent safety even at very high doses. IV studies showed doses up to 1260 mg were well tolerated with no serious adverse events.

Contraindications

  • xActive systemic infections
  • xSevere immunosuppression
  • xHypersensitivity to thymosin or any component
  • xPregnancy (insufficient safety data)

Decision Guide

Which is
right for you?

Choose Immunoxel (Dzherelo) if...

  • Adjunct immunotherapy alongside tuberculosis treatment
  • Immune restoration in HIV/TB coinfected patients
  • Reducing opportunistic infection rates
  • Supporting overall immune function during infectious disease treatment

Choose Thymosin Beta-4 if...

  • Recovering from injuries or surgery
  • Improving wound healing speed
  • Reducing inflammation
  • Minimizing scar formation